bupivacaine hydrochloride · Innocoll Pharms · NDA 209511
Xaracoll
Earliest generic entry, as listed
9 Jan 2033
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 11746141.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11746141 | drug product · sets the listed date | 9 Jan 2033 |
| US RE47826 | use U-2949 | 20 May 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 209511 · 001 · RLD · discontinued | implant, implantation | 100MG | 9 Jan 2033 |